Day: November 14, 2025

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q3 2025. Management Commentary: “Q3 reflects the continued progress of our strategy to build a diversified and sustainable biopharmaceutical business. We are pleased with the impact of our medical affairs initiatives and the strengthened engagement within the Canadian medical community, which have contributed to consecutive quarters of revenue growth in Canada. We also continued to translate our scientific leadership into tangible value through new IP and global collaborations. Despite short-term margin pressures, we remain confident...

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — “This quarter, we delivered strong net earnings that reflected the first full quarter of royalty revenue from the Borborema Gold Project and substantial investment gains across our mining portfolio.”, said Jonathan Goodman, President and Chief Executive Officer of Dundee Corporation. “With recurring cash flow now beginning to support our core cost base, we are in a stronger position to redeploy capital toward growth – reinforcing our ability to deliver sustained shareholder value.” “The announced acquisition of Maritime Resources by New Found Gold marks another pivotal validation of our long-term investment strategy.” Mr. Goodman continued. “We recognized the intrinsic value of Maritime early and supported the company through market cycles. The transaction highlights our ability to identify...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus  Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Strengthened balance sheet with $57.5 million financing to advance transplantation programs IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2025 operating and financial results and reviewed recent business highlights. “The results from our Phase 2 BESTOW trial demonstrated tegoprubart’s excellent efficacy and safety, importantly avoiding many of the long-term toxicities commonly seen with current standard-of-care...

Increased Profits in the Third Quarter 2025 SALT LAKE CITY, Nov. 14, 2025 (GLOBE NEWSWIRE) — OMNIQ Corp (OTCMTS: OMQS or “omniQ” or “the Company”) today announced its financial results for the third quarter 2025. The company reported $8.8 million in revenue and $3 million gross profit. The company continues to implement its cost-reduction strategy designed to strengthen profitability and support long-term operational efficiency. Financial HighlightsRevenue: $8.8 million compared to $9.5 million year-over-year. This was attributable to the focus on more profitable revenue and the timing of some orders. Gross Profit: $3 million compared to $2 million in the three-month period for 2024. Loss from Operations: $591 thousand compared to $787 thousand year-over-year. This represents a 13.7% improvement. Continued to focus on operational...

–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301– –Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients in Cohort 1 meeting the formal statistical criteria for response to BB-301– –First patient of Cohort 2 successfully treated with BB-301 in Q4 of 2025– –The Company raised approximately $100 million in an oversubscribed public offering of common stock, which is expected to fund advancement of the BB-301 Oculopharyngeal Muscular Dystrophy (OMPD) registrational program and associated regulatory filing activities– HAYWARD, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Benitec Biopharma...

SAN JOSE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the quarter ended September 30, 2025. As of September 30, 2025, the Fund’s net assets were $296,547, or $0.04 per share, compared with net assets of approximately $0.7 million, or $0.11 per share as of June 30, 2025. As of September 30, 2025, the Fund’s portfolio included public and private securities valued at $256,934, or $0.04 per share, which includes approximately $0.01 per share in cash and cash equivalents. Portfolio Summary (as of 9/30/25)Investment Fair Value1, Fair Value per Share1,2Equity/Debt Investments $197,925 $0.03Cash/Cash Equivalents $59,009 $0.01Other...